The impact of bevacizumab usage on patients who were curative resected for liver-confined metastases from colorectal cancer.

e14120 Background: We investigate whether there have been differences in disease-free survival (DFS) and overall survival (OS) among patients who were treated with different cytotoxic regimens (fluoropyrimidines alone or irinotecan or oxaliplatin based) with or without bevacizumab after complete resection of liver-confined metastases from colorectal cancer (CRC). Methods: Between May 2000 and July 2010, a total of 166 patients who underwent liver resection with curative intent from CRC were retrospectively analyzed. Results: Of the 166 patients, 70 were treated with oxaliplatin based regimens, 71 were irinotecan based and 25 were treated with fluoropyrimidines alone. With respect to bevacizumab usage, 72 were treated with cytotoxic regimens plus bevacizumab (BEV) while 94 were treated with cytotoxic regimens alone (NoBEV). After metastasectomy, the median follow-up time was 21 months, and the median OS and DFS were 54 months and 13 months, respectively. In the univariate analysis, no significant differenc...